all report title image

Colorectal cancer, or colon cancer, is a type of cancer that begins in the large intestine (colon). The colon is the final part of the digestive tract. The cancer often begins as a growth called a polyp inside the colon or rectum. Finding and removing polyps can prevent colorectal cancer. Colon cancer and rectal cancer are often grouped together because they have many features in common. Cancer starts when cells in the body start to grow out of control. Colonoscopy is a procedure to look inside the rectum and colon for polyps, or cancer. In this test, the rectum and entire colon are examined using a colonoscope, a flexible lighted tube with a lens for viewing and a tool for removing tissue. Colorectal cancer screening find problems that can be treated before cancer develops or spreads.

Market Statistics:

The global colorectal cancer screening market was valued at US$ 12,866.16 Mn in 2021 and is forecast to reach a value of US$ 21,135.40 Mn by 2028 at a CAGR of 7.5% between 2022 and 2028.

North America held dominant position in the global colorectal cancer screening market in 2020, accounting for 45.2% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Colorectal Cancer Screening Market Share (%), by Region, 2021

Colorectal Cancer Screening  | Coherent Market Insights

Recent Developments:

In September 2020, Exact Sciences Corporation acquired Base Genomics Ltd., an epigenetics company working to set the new standard in DNA methylation analysis, the most promising approaches to detecting cancer in its earliest stages.

In April 2020, Clinical Genomics expanded its strategic alliance for increased investment as well as expansion of commercialization of COLVERA colorectal cancer screening blood test monitoring outside the United States, Mexico, United Kingdom, and India.

Market Drivers:

  1. Increasing prevalence of colorectal cancer across the globe is expected to boost the growth of the global colorectal cancer screening market over the forecast period. For instance, in the United States, colorectal cancer is the third leading cause of cancer-related deaths in men and in women. According to the American Cancer Society, in 2022, there will be around 106,180 new cancer cases diagnosed and 52,580cancer deaths in the United States. As a result, there is an increasing demand for colorectal cancer screening in this region.
  2. Increasing demand for colorectal cancer screening tests is expected to augment the growth of the global colorectal cancer screening market over the forecast period. For instance, in May 2022, Guardant Health, Inc. announced the availability of Shield, the company’s first blood-based test for the detection of early-stage colorectal cancer. The test is intended for adults age 45 and older and those who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for colorectal cancer.
CMI table icon

Colorectal Cancer Screening Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 13,689.59 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 7.5% 2028 Value Projection: US$ 21,135.40 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Screening Tests: Stool-based Tests, Colonoscopy, CT Colonography (Virtual Colonoscopy), FlexibleSigmoidoscopy, and Other Screening Tests
  • By End User: Hospitals Independent Diagnostic Labs and Other End Users
  • By Geography: North America, South America, Europe, Asia-Pacific, and Middle East & Africa
Companies covered:

Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers AG, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, and Clinical Genomics Technologies Pty Ltd., among others

Growth Drivers:
  • Increasing prevalence of colorectal cancer
  • Increasing demand for colorectal cancer screening
Restraints & Challenges:
  • High cost of screening
  • Lack of awareness among people

Figure 2. Global Colorectal Cancer Screening Market Share (%), by Screening Test, 2021

Colorectal Cancer Screening  | Coherent Market Insights

Market Restraints:

  1. High cost of screening is expected to hinder growth of the global colorectal cancer screening market. Many countries, including the U.S. and the U.K., face challenge of providing care to a growing population of cancer patients due to expensive screening and treatment. According to the U.S. Centers for Disease Control and Prevention (CDC), April 2019 report, screening tests, on average, cost US$ 2,060 per person, ranging from US$ 1,057 for both tests to US$ 3,153 for colonoscopy. The average cost of Colonoscopy in India is INR Rs. 3,350. The maximum charge for Colonoscopy in India is up to INR Rs. 50,000.
  2. Lack of awareness among people about cancer screening is expected to hamper the growth of the global colorectal cancer screening market. For instance, regular screening, beginning at age 45, is the key to preventing colorectal cancer. The U.S. Preventive Services Task Force (Task Force) recommends that adults age 45 to 75 be screened for colorectal cancer. The Task Force recommends that adults age 76 to 85 talk to their doctor about screening.

Market Opportunities:

  1. Increasing cancer prevention initiatives are expected to offer lucrative growth opportunities for player in the colorectal cancer screening market. For instance, in 2021, the US government declared March as the National Colorectal Cancer Awareness Month to increase awareness on colorectal cancer management. It is a chance to bring greater attention to this terrible disease and to offer access to lifesaving screening, care, and treatment.
  2. Technological advancements in colorectal cancer screening are expected to offer significant growth opportunities for player in the global colorectal cancer screening market. For instance, in April 2021, the U.S. Food and Drug Administration (FDA) announced the approval of GI Genius, a device using artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon during a colonoscopy.

Market Trends/Key Takeaways:

  1. Growing geriatric population across the globe is expected to boost the growth of the global colorectal cancer screening market. For example, the greatest burden of colorectal cancer falls on the elderly, with about 70% of cases diagnosed in people aged 65 years and more and 40% diagnosed in people over the age of 75. While, approximately 75% of colorectal cancer deaths occur in people older than 65 years of age.
  2. Research and development in cancer screening/diagnostics is expected to drive growth of the global colorectal cancer screening market. For example, in February 2021, The EU set out a €4 billion Beating Cancer plan, including the most concerted push ever for research and its translation through to better treatments. The plan will fund technology development, improve access to therapies, create new research networks, promote disease prevention, and offer better support for people who survive cancer.

Competitive Landscape:

  1. Clinical Genomics Technologies Pty Ltd
  2. Epigenomics Inc.
  3. Exact Sciences Corporation
  4. Hemosure Inc.
  5. Novigenix SA
  6. Quidel Corporation
  7. Siemens Healthineers AG
  8. Sysmex Corporation
  9. Eiken Chemical Co. Ltd
  10. Polymedco Inc
  11. Olympus Corporation

Colorectal cancer is a type of cancer that begins in the large intestine (colon). The cancer can also be called colon cancer or rectal cancer, depending on where they start. Colorectal cancer screening is important because when found early, colorectal cancer is highly treatable. Early stages of colorectal cancer usually present no symptoms. Regular screenings may reduce the risk for death and complications caused by colorectal cancer. Screening help find cancer at an early stage, before symptoms appear. If the cancer is diagnosed at a localized stage, the survival rate is 90%. If the cancer spread to surrounding tissues or organs and/or the regional lymph nodes, the 5-year survival rate is 73%. If the cancer has spread to distant parts of the body, the 5-year survival rate is 17%.

Market Dynamics:

Increasing prevalence of colorectal cancer, increasing cancer prevention initiatives, and rise in awareness among people about colorectal cancer screening are some major factors expected to aid in the growth of the global colorectal cancer screening market during the forecast period. For instance, colorectal cancer can be a deadly disease, but without proactive screenings, it’s one that often goes unnoticed or undiagnosed in its early stages. Screenings are the No. 1 way to detect colorectal cancers and in most cases are covered 100% by most insurance plans. The US government, in 2021, declared March as the National Colorectal Cancer Awareness Month to increase awareness on colorectal cancer management, bringing attention to colorectal cancer, the third most commonly diagnosed cancer in the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global colorectal cancer screening market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global colorectal cancer screening market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, and Clinical Genomics Technologies Pty Ltd., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global colorectal cancer screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global colorectal cancer screening market.

Detailed Segmentation:

  • Global Colorectal Cancer Screening Market, By Screening Tests:
    • Stool-based Tests
    • Colonoscopy
    • CT Colonography (Virtual Colonoscopy)
    • Flexible Sigmoidoscopy
    • Other Screening Tests
  • Global Colorectal Cancer Screening Market, By End User:
    • Hospitals Independent Diagnostic Labs
    • Other End Users
  • Global Colorectal Cancer Screening Market, By Geography:
    • North America
    • South America
    • Europe
    • Asia-Pacific
    • Middle East & Africa

Frequently Asked Questions

The global colorectal cancer screening market size is estimated to be valued at US$   13,689.59 Million in 2022 and is expected to exhibit a CAGR of 7.5%between 2022 and 2028.
Increasing prevalence of colorectal cancer and high demand for colorectal cancer screening are fueling the growth of the market.
The Colonoscopy segment is the leading screening test segment in the market.
High cost of screening and lack of awareness among people are the major factors restraining growth of the market.
Major players operating in the market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers AG, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, and Clinical Genomics Technologies Pty Ltd., among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo